210 related articles for article (PubMed ID: 9389404)
1. Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations.
Alemany R; Dai Y; Lou YC; Sethi E; Prokopenko E; Josephs SF; Zhang WW
J Virol Methods; 1997 Nov; 68(2):147-59. PubMed ID: 9389404
[TBL] [Abstract][Full Text] [Related]
2. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
[TBL] [Abstract][Full Text] [Related]
3. Replication and packaging of helper-dependent adenoviral vectors.
Sato M; Suzuki S; Kubo S; Mitani K
Gene Ther; 2002 Apr; 9(7):472-6. PubMed ID: 11938462
[TBL] [Abstract][Full Text] [Related]
4. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis.
Fisher KJ; Choi H; Burda J; Chen SJ; Wilson JM
Virology; 1996 Mar; 217(1):11-22. PubMed ID: 8599194
[TBL] [Abstract][Full Text] [Related]
5. A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles.
Murakami P; Pungor E; Files J; Do L; van Rijnsoever R; Vogels R; Bout A; McCaman M
Hum Gene Ther; 2002 May; 13(8):909-20. PubMed ID: 12031124
[TBL] [Abstract][Full Text] [Related]
6. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein.
Hodges BL; Serra D; Hu H; Begy CA; Chamberlain JS; Amalfitano A
J Gene Med; 2000; 2(4):250-9. PubMed ID: 10953916
[TBL] [Abstract][Full Text] [Related]
7. Development of a size-restricted pIX-deleted helper virus for amplification of helper-dependent adenovirus vectors.
Sargent KL; Ng P; Evelegh C; Graham FL; Parks RJ
Gene Ther; 2004 Mar; 11(6):504-11. PubMed ID: 14999222
[TBL] [Abstract][Full Text] [Related]
8. 'Autoreplication' of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes.
Marienfeld U; Haack A; Thalheimer P; Schneider-Rasp S; Brackmann HH; Poller W
Gene Ther; 1999 Jun; 6(6):1101-13. PubMed ID: 10455413
[TBL] [Abstract][Full Text] [Related]
9. Development of a FLP/frt system for generating helper-dependent adenoviral vectors.
Ng P; Beauchamp C; Evelegh C; Parks R; Graham FL
Mol Ther; 2001 May; 3(5 Pt 1):809-15. PubMed ID: 11356086
[TBL] [Abstract][Full Text] [Related]
10. Production of helper-dependent adenovirus vector relies on helper virus structure and complementing.
Zhou HS; Zhao T; Rao XM; Beaudet AL
J Gene Med; 2002; 4(5):498-509. PubMed ID: 12221643
[TBL] [Abstract][Full Text] [Related]
11. Gutted adenoviral vector growth using E1/E2b/E3-deleted helper viruses.
Barjot C; Hartigan-O'Connor D; Salvatori G; Scott JM; Chamberlain JS
J Gene Med; 2002; 4(5):480-9. PubMed ID: 12221641
[TBL] [Abstract][Full Text] [Related]
12. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus.
Cheshenko N; Krougliak N; Eisensmith RC; Krougliak VA
Gene Ther; 2001 Jun; 8(11):846-54. PubMed ID: 11423932
[TBL] [Abstract][Full Text] [Related]
13. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
14. Differential amplification of adenovirus vectors by flanking the packaging signal with attB/attP-PhiC31 sequences: implications for helper-dependent adenovirus production.
Alba R; Hearing P; Bosch A; Chillon M
Virology; 2007 Oct; 367(1):51-8. PubMed ID: 17560622
[TBL] [Abstract][Full Text] [Related]
15. A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors.
Zhou H; Beaudet AL
Virology; 2000 Sep; 275(2):348-57. PubMed ID: 10998335
[TBL] [Abstract][Full Text] [Related]
16. A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells.
Marzio G; Kerkvliet E; Bogaards JA; Koelewijn S; De Groot A; Gijsbers L; Weverling GJ; Vogels R; Havenga M; Custers J; Pau MG; Guichoux JY; Lewis J; Goudsmit J
Vaccine; 2007 Mar; 25(12):2228-37. PubMed ID: 17250936
[TBL] [Abstract][Full Text] [Related]
17. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
18. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration.
Parks R; Evelegh C; Graham F
Gene Ther; 1999 Sep; 6(9):1565-73. PubMed ID: 10490766
[TBL] [Abstract][Full Text] [Related]
19. Degenerated pIX-IVa2 adenoviral vector sequences lowers reacquisition of the E1 genes during virus amplification in 293 cells.
Robert JJ; Gauffeny I; Maccario J; Jullien C; Benoit P; Vigne E; Crouzet J; Perricaudet M; Yeh P
Gene Ther; 2001 Nov; 8(22):1713-20. PubMed ID: 11892839
[TBL] [Abstract][Full Text] [Related]
20. Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system.
Ng P; Evelegh C; Cummings D; Graham FL
J Virol; 2002 May; 76(9):4181-9. PubMed ID: 11932383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
